NEA Management Company’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,437,689
| Closed | -$9.75M | – | 31 |
|
|
2025
Q2 | $9.75M | Hold |
2,437,689
| – | – | 0.73% | 21 |
|
|
2025
Q1 | $2.22M | Hold |
2,437,689
| – | – | 0.17% | 31 |
|
|
2024
Q4 | $6.75M | Hold |
2,437,689
| – | – | 0.38% | 31 |
|
|
2024
Q3 | $12.7M | Hold |
2,437,689
| – | – | 0.69% | 24 |
|
|
2024
Q2 | $10.9M | Hold |
2,437,689
| – | – | 0.82% | 23 |
|
|
2024
Q1 | $18.7M | Hold |
2,437,689
| – | – | 1.16% | 23 |
|
|
2023
Q4 | $10.4M | Hold |
2,437,689
| – | – | 0.69% | 29 |
|
|
2023
Q3 | $10.2M | Hold |
2,437,689
| – | – | 0.79% | 27 |
|
|
2023
Q2 | $13.6M | Hold |
2,437,689
| – | – | 1.04% | 24 |
|
|
2023
Q1 | $14M | Hold |
2,437,689
| – | – | 0.97% | 25 |
|
|
2022
Q4 | $2.56M | Sell |
2,437,689
-6,690
| -0.3% | -$11.7K | 0.14% | 46 |
|
|
2022
Q3 | $6.55M | Hold |
2,444,379
| – | – | 0.33% | 39 |
|
|
2022
Q2 | $10.5M | Hold |
2,444,379
| – | – | 0.54% | 34 |
|
|
2022
Q1 | $10M | Hold |
2,444,379
| – | – | 0.29% | 42 |
|
|
2021
Q4 | $16.7M | Hold |
2,444,379
| – | – | 0.34% | 36 |
|
|
2021
Q3 | $28.3M | Hold |
2,444,379
| – | – | 0.34% | 28 |
|
|
2021
Q2 | $41.7M | Hold |
2,444,379
| – | – | 0.54% | 28 |
|
|
2021
Q1 | $48.4M | Hold |
2,444,379
| – | – | 1.09% | 23 |
|
|
2020
Q4 | $50.5M | Hold |
2,444,379
| – | – | 1.33% | 21 |
|
|
2020
Q3 | $64.3M | Buy |
+2,444,379
| New | +$60.7M | 2.72% | 17 |
|
NEA Management Company's INZY Position: Q3 2025 in Review
NEA Management Company sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 2,437,689 shares — an estimated $9.75M sold.
NEA Management Company first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $64.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- NEA Management Company reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- NEA Management Company sold 2,437,689 Inozyme Pharma shares in Q3 2025, an estimated $9.75M.
- NEA Management Company first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- NEA Management Company's Inozyme Pharma position peaked at $64.3M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on NEA Management Company's 13F filing for Q3 2025, filed 14 Nov 2025.